25H-NBOMe

25H-NBOMe is a psychedelic drug and derivative of the phenethylamine chemical class. It is known for its potent hallucinogenic effects and its use as a designer drug. The compound was first synthesized in 2003 by Ralf Heim at the Free University of Berlin, but it did not gain popularity in the recreational drug market until around 2010.

Chemistry

25H-NBOMe is a derivative of the 2C family of phenethylamines, specifically 2C-H. It is part of the NBOMe series of psychedelic phenethylamines, all of which are derivatives of the 2C family. The NBOMe series includes several other compounds, such as 25I-NBOMe and 25C-NBOMe, which have similar structures and effects.

Pharmacology

The pharmacology of 25H-NBOMe is not fully understood. It is known to act as a highly potent partial agonist for the 5-HT2A receptor, which is thought to be responsible for its hallucinogenic effects. The drug has a high affinity for this receptor, which means it binds to it very strongly, leading to intense and long-lasting effects.

Effects

The effects of 25H-NBOMe can vary greatly depending on the dose, the individual's physiology, and the method of administration. Common effects include intense visual hallucinations, altered perception of time, euphoria, and cognitive enhancement. However, the drug can also cause negative effects such as anxiety, paranoia, and potentially dangerous increases in heart rate and blood pressure.

Legal Status

The legal status of 25H-NBOMe varies by country. In many countries, including the United States, it is a controlled substance. In others, it is legal to possess but not to sell or manufacture.

Health Risks

25H-NBOMe is considered to be a highly dangerous drug due to its potency and unpredictability. There have been numerous reports of hospitalizations and deaths associated with its use. The most common cause of death is acute toxicity, often resulting from an overdose.

See Also

• Psychedelic drug
• Designer drug
• Hallucinogen
• NBOMe
• Phenethylamine